Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Detection of change in SPARCC MRI SSS and discrimination of the SSS in 147 patients with axial spondyloarthritis receiving either standard or TNFα inhibitor therapy

From: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis

  SDC (% maximum range) Mean (SD) baseline score P value Mean (SD) change score Guyatt’s Effect size P value
   Anti-TNFαa Standardb   Anti-TNFαa Standardb   
Fat metaplasia 2.2 (5.5%) 3.6 (5.1) 4.0 (6.6) NS 0.7 (2.2) 0.2 (1.5) 0.5 0.017
Backfill 2.8 (14%) 3.7 (4.5) 2.2 (3.1) 0.08 0.1 (2.9) 0.4 (1.9) 0.03 NS
Erosion 3.05 (7.6%) 2.7 (3.2) 3.6 (4.4) NS −1.5 (2.8) −0.5 (2.7) 0.6 0.017
Ankylosis 1.39 (7%) 7.3 (8.5) 4.1 (7.0) 0.02 0.4 (1.6) 0.3 (1.2) 0.3 NS
  1. MRI, magnetic resonance imaging; NS, not significant; SD, standard deviation; SDC, smallest detectable change; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, Sacroiliac Joint Structural Score; TNF α, tumor necrosis factor alpha. aPatients receiving TNFα inhibitor therapy (n = 79). bPatients receiving standard therapy (nonsteroidal anti-inflammatory drug and/or physiotherapy, n = 68).